Who are we? ChiraTecnics was founded in 2009 by Prof. Anthony Burke as a spin-out from the University of Évora, with the aim to manufacture and commercialise ligands, building blocks and catalysts for chiral synthesis. Whilst the company still offers this portfolio to clients, it now mainly focuses on custom synthesis programmes to support medicinal chemistry and drug discovery projects for pharmaceutical and biotech companies. It is led by a strong international team and has access to all vital equipment to implement our projects. |
News May 2017 The 2nd edition of the International conference on Synthesis and Catalysis (ISySyCat2017) will take place at the University of Evora from 5-8 Sept. 2017. Hope to see you there, we will: http://isysycat2017.eventos.chemistry.pt/
April 2015 We have signed a contract with the University of Évora, to commercialise some novel patented state-of-the-art chiral organocatalysts that are used in a efficient safe process (WO2015052656 (A1)) to give chiral amines in good yields with very good enantiocontrol. These catalysts can also be immobilized.
Replica Hermes Kelly Bags Jan 2015 Chiral small molecules are still very important in the pharmaceutical industry. It was recently reported (R. Mullin, Chem. & Eng. News, Dec 8, 2014, Mixed Signals), that fluticasone, rosuvastatin and esomeprazole were the third, sixth and seventh top-selling pharmaceutical compounds for the 12 month period ending on the 30th June 2014. They had combined sales of 25.1 billion USD. |
|
 |
|
|
Did you Know?
The CRO Market for API and other chemicals is buzzing at the moment. Revenues in 2010 were $11.43 billion and it is estimated to reach $20.09 billion in 2020. Pharma is outsourcing more and more business to competent CROs. |
Our mission is to provide
|
|